AMLN Stock Report
2-Year Price History
Recent Price
(6/23 4:00PM)
-0.8%
$11.84
52-Week Price
$5.50 – $35.00
Market Capitalization
$1.7 Billion
Most Recent Dividend
$0.00
Ockham’s Rating
Rating specific information requires Premium Access.
Buy Now or
Take the Tour.
AMLN Revenue
As a value investing shop, we are interested in seeing how AMLN’s revenues measure up against past performances. One easily understandable way of doing that is to compare Price to Sales per share levels over a given time frame. Assuming it is available, Ockham prefers to look at ten years of history (for this stock there are 8 years of history available) and we weigh recent years more heavily. This allows us to find weighted average historical high and low Price to Sales ratios, which give us a better idea of the stock’s current underlying value. Using this method, we have established a high range for Price to Sales of 25.25x and the low end of the range at 12.41x.
With respect to these historically rational metrics, notice that the current Price to Sales per share ratio for AMLN of 2.08x is well below its normal historic Price to Sales levels. At a price of $12.34, AMLN is 89% below where we would expect to see it. Clearly, this stock looks undervalued compared to historical levels, at least on a Price to Sales basis. This will positively affect our analysis because it is rare to find a stock this far below historical norms, and we would expect some price appreciation to bring this metric back towards a more normal range.
AMLN Cash Earnings
Price to Cash Earnings analysis is inappropriate for this company due to an insufficient positive cash earnings history. Rather than calculating a potentially misleading Price to Cash Earnings analysis, we have chosen to give AMLN a neutral Price to Cash Earnings outlook at this time. However, we should point out that this metric is a significant element in Ockham’s methodology to analyzing the outlook for any company. Therefore, for AMLN, our assessment is now more dependent on the Price to Sales analysis, and investors should be cautious with a company with very limited, if any, positive cash earnings.
AMLN Dividends
When determining a company’s future prospects for success, Ockham Research sees analysis of dividend payments as a key additional factor. Even though it isn’t imperative for AMLN to shell out a dividend in order to receive a positive rating, it can be helpful to further our analysis. As of the time of this report, our data provider does not have historical data for AMLN. Therefore, we are not utilizing the dividends portion in our study. So, we do not know whether AMLN currently pays a dividend at present or not, we have an "expected dividend" payment listed in key fundamentals but cannot varify it.
The latest TV Media Discussion
“…Weight loss was kind of comparable over six month’s 7 pounds down on novo’s 6.4 pounds down on AMYLIN and lilly’s drug. Events. Victozasy is awaiting fda …” …more details…
“…So you can inject one time each day or one time each week, to me it’s a no brainer. >> long-acting release, sounds like you’re putting your money on AMYLIN. >> that’s correct. >> moving on, you have been bearish on inhaleable inlynn. …” …more details…
“…Similar drug of its own? >> eli lilly is very committed. We recently announced we’re forming a brand new business unit in san diego made up of lily and AMYLIN employees. We renegotiated a number of aspects of our relationship with >> and then finally, do you believe that it is carl icahn’s …” …more details…
“…Dual with the first-ever one a day drug for diabetes from novo he joined me, dan brad berry, the ceo of AMYLIN pharmaceutical good morning to you. >> before we get to that battle I have to talk to you about this proxy battle. With carl icahn and east born …” …more details…
“…Association meeting in new orleans with t. Another cnbc exclusive. >> good morning, rebecca. AMYLIN PHARMACEUTICALS and eli lilly recently filed for fda approval for the first ever once a week drug for long-acting release drug. But it consumed the engaged in a …” …more details…
“…A week drug for that disease. Coming up next, when "squawk on the street" continues, a cnbc exclusive live interview with the ceo of the company behind that drug, we’re talking AMYLIN PHARMACEUTICALS …” …more details…
“…Trends continue to come on to the down side shares are down 1.3%, on the flip side, we’ve got a lot of clinical trial data putting a lot of focus on medical movers and AMYLIN, positive news about the diabetes drug, we’ve got arena getting some positive results with its obesity drug, micromet, also clinical trial results and …” …more details…
“…>>> up next, is the recent surge in stock overdone? Investors contemplating that question. We’ll get the word on the >>> and then AMYLIN PHARMACEUTICALS brace for a battle royale over the diabetes the ceo joins us. And the hidden casualties of the …” …more details…
“…Be live at the american diabetes orleans with an exclusive interview with AMYLIN ceo dan bradberry. >> I would say one thing as one member approximate of the board of motorola, you’ve seen …” …more details…
“…>> mr. Icahn, what can you really accomplish here with two dissident board members on a 12-member board on AMYLIN? I mean, it’s not even close to being a majority. >> I think you accomplish a lot I do think that boards in general …” …more details…
“…He’s fighting to get four of his people on the board of biogen to get the company to reincorporate into what he thinks is a shareholder friendly state. He thinks that AMYLIN PHARMACEUTICALS one week ago dodd today when they each won a seat on that board and ousted the current chairman and the lead independent director. …” …more details…
“…Having as much of an influence. That would be a good thing from my point of view, hope that shareholders take the time to make their own decisions. We’ll see. During this week we also saw AMYLIN, reported quite a bit on carl icon got one board seat. I believe riskmet trilks saidrics said, hey, go for three board seats. …” …more details…
“…Leap 6.2% to the downside. Increased the shares of their secondary offering to $7 you see the impact of the AMYLIN, quickly, east four capital and carl icon reportedly got a seat each on their board. We still have at venture. This my mike huckman nugget of …” …more details…
“…Good night. >> announcer: this is cnbc.Com >>> ten-year treasury yields rise to over 3.7% as investors worry about increased government >>> AMYLIN PHARMACEUTICALS said it appears two of five dissident nominees have been elected to its board in a fight with carl icahn and eastbourne capital …” …more details…
“…Born are are already talking to potential suitors for the my sources tell me there are four to seven companies that are definitely interested in buying AMYLIN. They see what they have and they see what the pipeline is. >> four to seven companies. After AMYLIN has its sites set once again and tried and failed to get the company sold last …” …more details…
“…>> good morning. After weeks of an else a lating war of words and proxy points including paul icon and AMYLIN PHARMACEUTICALS, the meeting is set in an hour from now. AMYLIN shares from lost tlrlt of their value, I guess can’tly underperforming the nasdaq biotech index. A big reason is that the safety issue over the AMYLIN top drug which is made with synthetic there have been a small number of chances of things that have hurt sales. AMYLIN and partners lilly has recently filed for fda approval of one a week version of byetta. Icon and east born capital which own 20% of AMYLIN shares are frustrated we the stock price and the pace in progress and they want to put their own people on the board. David has been following AMYLIN for years, thinks the vote might be closer than most people expect but icon and east born may come out on top. …” …more details…
“…>>> and later, two activist investors, down more than 60% over the past year, they’re demanding some big changes. The latest with AMYLIN’s annual meeting. …” …more details…
“…He tried to put this company with greenbriar a while back and people are speculating about that again. He’s got light on his plate he’s battling AMYLIN PHARMACEUTICALS. He’s got a little battle going with lion gate, biogenetic. But get carl in there, he shakes things up. He’s a big friend of the show, insight on that. …” …more details…
“…>> cheryl: making amen pharmaceuticals, can you >> I don’t know how to say there’s no truth to that. We like our AMYLIN relationship the way it is. They have a number of issues with shareholders. What we’re focusing on with AMYLIN is selling more. >> cheryl: I had to ask you. As a company five years ago you were at 75 bucks a share. You’re well off that now. You’re down — the stock of AMYLIN. So you don’t want to buy AMYLIN but eli lilly, you’re in the $75 what do you say to shareholders probably nervous with a nice …” …more details…
“…Directors and trying to profit from short-term gains and we’ve heard this back and forth and the shareholders coming into being and trying to push something at AMYLIN, a trend we’ve been seeing in light of this volatility in the markets. Back over to you. >> thank you very much. Shibani joshi and a nice segway off the story, breaking news out of pepsi. …” …more details…
“…Week baeda if it wins fda approval could be a blockbuster, maybe even a megablockbuster, in sales. AMYLIN, lilly, and there’s a third partner on this drug, today lilly’s ceo told david faber on "street signs" he thinks it could take about a …” …more details…
“…Catch-up, this stock’s well over ten bucks i’m watching this they’re speaking by the way at a barclays conference tomorrow. >> good to know. Trade number two here, a real epidemic. Eli lilly and AMYLIN filing for approval after a once a week version of its popular dibeeths drug baeda. What chances does it stand for approval and what could it mean to the bottom line? …” …more details…
“…Medicine out to people who can benefit from it. >> nonetheless as is the case, biopharma investors looking ahead. Today shares of lilly, AMYLIN and al kerrmes. Waiting for the similar one a day drug. …” …more details…
“…You would just have to take this drug once a week, inject it into your stomach once a week, and then you are done in terms of regulating your blood sugar level. Secondly, AMYLIN did announce last week it’s laying off 35% of its sales force as this company is engaged in a very nasty proxy fight with karl ikon at the moment. …” …more details…
“…About the potential for a flu this is a disease most experts say is a global epidemic now. Diabetes. Eli lilly, AMYLIN PHARMACEUTICALS have just announced they’ve applied for fda administration approval of the first ever once a week treatment for diabetes. This would be a once a week …” …more details…
“…A-mag pharmaceuticals up 50% the fda gave the company okay to make a manufacturing facility for one of the anemia drugs, AMYLIN, you know it’s in a proxy fight with carl icahn and the company sent a letter to shareholders saying they should reject icahn’s board nominee, we’ll keep you posted on that ongoing story. …” …more details…
“…Biotech news. Riding high is acorda. Carl icahn sent a letter to AMYLIN allowing him to speak to east cital without poison pill kicking in. There are headlines crossing every minute with the ongoing battle. >> liz: carl icahn has spoken to us last week specifically he was very angry, saying that AMYLIN management was acting like a dictatorship. Not allow ing allowing people to talk amongst themselves. …” …more details…
“…Earning season and qualcomm says it’s going to delay quarterly numbers until monday because of legal reasons, but the company said it’s going to meet or beat and AMYLIN says there’s been no agreement in the proxy fight just yet, with carl icahn, so, a war still wages on between amazon, sorry, AMYLIN and carl icahn, but of course, earnings really in focus right now. Back to you, alexis. Alexis: thank you very much. Shibani. Let’s head out to the cme group and check once again with lincoln elliss with the lincoln group. …” …more details…
“…Big cap cash rich biotech was up 23 points as a group while the rest of the market — >> gilliad. >> and even weak companies like AMYLIN. >> too late to get in >> no they’re a premier pharmaceutical compapany in the cash rich, no debt. Pipeline. Last year they did well if …” …more details…
“…They were upgraded by lezard. Amly amlyn. Carl icahn saying in the last five or ten minutes he will respond to AMYLIN’s letter. Back and forth but an internal battle brewing for AMYLIN PHARMACEUTICALS. Up 1%. Predominantly a lot of selling in the session. >> cheryl: look at denddrion. They’ve been public a week and the stock is shooting …” …more details…
“…Not go for control of the company. But having representatives — i’m sure there are board members that are good on AMYLIN, but I think if you read about a board member that resigned, he was saying that cook has done an abombal job. >> you’re calling for the …” …more details…
“…Start making money. Interestingly, liz. There will 339 companies last — 39 companies responsible for the best-selling products. Out of the 39, AMYLIN is the only one that doesn’t show a profit. What does it tell you? …” …more details…
“…Difficult to do. >> it’s impalling for investors. What is the number one accusation about the management at AMYLIN? >> I think a lot of things have been done at AMYLIN that are wastewasteful. A lot of course that commire out. …” …more details…
“…Cp >> liz: the market is up 137 we’ve had a great rally over march. Shares of biotech company AMYLIN have fallen 17% over the last eight months. And one investor is not standing by watching the freefall, it’s carl icahn who is on AMYLIN board and owns 10% of the company. He wrote a scathing letter yesterday, I have it in my hand, urging joe kef cook to resign and he writes like an imperil chairman you have taken steps to entrench …” …more details…
“…Market is up 121 points. But we’ve got the fox business exclusive with carl icahn coming up. He’s got two different actually, a couple here brewing with AMYLIN PHARMACEUTICALS and biogenitech. Find out what he wants to win from the fight and how does he view the investment picture now? Next on "countdown to the …” …more details…
“…Biotech is a sector at the I know you will talk to carl icahn, liz, and, ouster trying to get rid of the AMYLIN chairman and ceo. That’s one reason they’re in the red. He has a proxy battle. But they won’t show a sale. …” …more details…
“…Reference that carl icahn AMYLIN pharmaceutical breaking news as we’re doing our interview, wrapping up the interview with mark wagner, you know, carl icahn bias into companies, sends to be an activist investor. Well, he’s been buying into AMYLIN PHARMACEUTICALS and what icahn is saying is that three of the board seats for AMYLIN, actually a pretty big company, not necessarily a household name. Pretty big, three of the board seats there need to change so carl icahn stepping up the eat on AMYLIN PHARMACEUTICALS. Maybe not a deal yet, dagen, but some sort of carpet raider type news, it feels like we’re getting back to normal with …” …more details…
“…Surgical because all three were downgraded talking about%"yx biopharma stocks. But intuitive down 2.5. AMYLIN down 0.5%. I want to mentiontryrcw, the big trucking company down 25%. It’s worsened as the day progressed. …” …more details…
“…It will add at least 30 cents to eps in 2013 and 2014. Meantime, jpmorgan’s biotech analyst said lilly and AMYLIN raised their prices by 6.5% last friday but that news is obviously not helping shares of either company. Check out my blog on cnbc.Com. …” …more details…
“…>> it has been a while. >> he’s blowing us up, I think. >> no, no, let’s not say that. He’s coming on wednesday. A lot of boards he’s fighting. Stuff like that. >> you know he’s gotten the AMYLIN. >> he’s a little busy. >> in proxy battles. >> he’s tweeting the yahoo! Kid. >>> moving on, next trade, credit card charging high therweek. Visa up 11%. All in the face of, yes, the …” …more details…